You are here

Our science / Clinical Trials / Find a Trial / NCT01918202

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers

Back to Search Print Save as PDF Bookmark Trial

NCT01918202

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Karolinska Trial Alliance (KTA) M62
Huddinge, Stockholm, SE- 141 86 Sweden
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- healthy male volunteers

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of orthostatic hypotension

- History of prior radiation exposure for research purposes, or radiation therapy

NCT01918202
Pfizer
Completed
A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Normal Healthy
Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects
NCT02871037
All Genders
18+
Years
New Haven, Connecticut
Healthy Volunteers
Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
NCT03184168
Males
18+
Years
Madison, Wisconsin
Healthy
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
NCT03146065
All Genders
18+
Years
Brussels,
Healthy
Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects
NCT03534648
All Genders
18+
Years
Brussels,
A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers
A Phase 1, Open-label Adaptive Design Study To Evaluate Pde10 Enzyme Occupancy As Measured By Positron Emission Tomography (Pet) Following Single Oral Dose Administration Of Pf-02545920 In Healthy Male Subjects
This Phase 1 study will evaluate PDE10 enzyme occupancy using Positron Emission Tomography after a single dose of PF-02545920 in Healthy male volunteers.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Healthy
  • Drug: 20 mg PF-02545920
    Subject will receive a single dose of 20 mg PF-02545920.
  • Drug: PF-02545920

    The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.

    This cohort is optional.

  • Drug: PF-02545920
    The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
  • Experimental: Cohort 1 - 20 mg
    Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
    Intervention: Drug: 20 mg PF-02545920
  • Experimental: Cohort 2 ( adaptive dose, optional)
    Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
    Intervention: Drug: PF-02545920
  • Experimental: Cohort 3 ( adaptive dose, optional)

    Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.

    Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional

    Intervention: Drug: PF-02545920
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
9
September 2014
September 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy male volunteers

Exclusion Criteria:

  • History of orthostatic hypotension
  • History of prior radiation exposure for research purposes, or radiation therapy
Sexes Eligible for Study: Male
21 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Sweden
 
 
NCT01918202
A8241017
2013-002733-38 ( EudraCT Number )
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2014

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now